Encysive Thelin PAH submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Encysive submits its oral endothelin receptor antagonist Thelin (sitaxsentan) for treatment of pulmonary arterial hypertension, the firm announces May 25. The NDA "contains the largest database ever assembled in a regulatory filing for PAH, with approximately 900 PAH patients receiving Thelin," the Houston-based company said. The NDA includes two pivotal trials, the second of which (STRIDE-2) was conducted under a special protocol assessment with FDA (1Pharmaceutical Approvals Monthly September 2004, In Brief). Thelin would be entering an increasingly competitive market: CoTherix' inhaled prostacyclin Ventavis (iloprost) cleared FDA last December (2Pharmaceutical Approvals Monthly January 2005, p. 3) and Pfizer's Revatio (sildenafil) cleared FDA June 3 (see related brief, p. 15)...
You may also be interested in...
Myogen Ambrisentan On-Track For Late 2006 Pulmonary Hypertension NDA
Myogen appears on-track to file ambrisentan for treatment of pulmonary arterial hypertension by year-end 2006
Encysive Thelin pivotal trial
Encysive plans to submit an NDA for Thelin (sitaxsentan) for pulmonary arterial hypertension "on or around the end of the first quarter in 2005." The company, formerly Texas Biotech, announced enrollment was complete for the Phase III Sitaxsentan To Relieve ImpaireD Exercise (STRIDE-2) study Sept. 8. The 240-patient, 18-week, double-blind, placebo-controlled trial includes a "third party bosentan [Actelion's Tracleer] arm," Encysive says. Topline data are expected in February 2005. The confirmatory trial is being conducted under FDA's special protocol assessment program (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 17)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”